News Search Results
Oct 27, 2025, 11:11 ET Shareholder Alert: The Ademi Firm investigates whether Cadence Bank is obtaining a Fair Price for its Public Shareholders
In the transaction, Cadence shareholders will receive 2.475 shares of common stock for each outstanding share of Cadence common stock. Based on Huntington's closing price of $16.07 as of October 24, 2025, the consideration implies $39.77 per Cadence share. Cadence insiders will
More news about: Ademi LLP
Oct 27, 2025, 07:00 ET Huntington Bancshares Incorporated to Acquire Cadence Bank
Launched in 2010, Huntington's pioneering Fair Play philosophy focuses on providing services without hidden fees or asterisks and delivering fair and safe access to banking for consumers. Through this combination, Cadence customers will have access to Huntington's full suite of Fair Play product
More news about: Huntington Bancshares Incorporated
Oct 24, 2025, 14:00 ET Huntington Bank Appoints Joe Nimmons to Lead New Regional Community Lending Group; Brian Kelso Named Regional President for Colorado Region
presence in Colorado. Named Colorado regional president in 2022, Nimmons has helped drive growth and strengthen Huntington's brand in the region. His leadership has been integral to expanding Huntington's lending programs, building local partnerships and advancing economic opportunities across Colorado.
More news about: Huntington Bank
Oct 23, 2025, 16:30 ET Huntington Bank Announces Treasury Management Connectivity Ecosystem to Empower Businesses with More Sophisticated, Personalized Financial Intelligence
Huntington's new Connectivity Ecosystem will deliver more seamless integration and greater control to businesses for faster, data-driven decisions COLUMBUS,
More news about: Huntington Bancshares Incorporated
Oct 23, 2025, 09:00 ET Alloy Partners and Huntington Bank Launch New Venture Studio to Accelerate Innovation and Growth Across Banking
Parker, CEO of Alloy Partners. "This venture studio is not just about launching new businesses, it's about embedding innovation deep into the DNA of Huntington's growth story. Together, we're creating a repeatable engine to turn bold ideas into real-world outcomes." The collaboration
More news about: Alloy Partners
Oct 21, 2025, 11:50 ET Pioneering Physician-Scientist Dr. Francis S. Collins Joins ImmunoBrain Board of Directors
Michigan and the NIH for 41 years, doing groundbreaking research on type 2 diabetes and discovering the gene misspellings that cause cystic fibrosis, Huntington's disease, progeria, and several other disorders. A former director of the National Human Genome Research Institute, Dr. Collins coordinated an international
More news about: ImmunoBrain Checkpoint Inc.
Oct 20, 2025, 08:00 ET Huntington Bank Completes Merger with Veritex, Deepening Commitment to Texas
Acquisition accelerates Huntington's growth initiatives in dynamic Texas markets COLUMBUS, Ohio, Oct. 20, 2025
More news about: Huntington Bancshares Incorporated
Oct 20, 2025, 06:13 ET Groundbreaking Study in the Journal of Clinical Investigation Advances Cell Therapy for Huntington's Disease Treatment
authentic medium spiny neurons (MSNs) and provides comprehensive mechanistic insights that underpin cell-replacement therapy for Huntington's disease. Huntington's disease (HD), an autosomal dominant neurodegenerative disorder, has a global prevalence of 5-10 cases per 100,000 people.
More news about: UniXell Biotechnology
Oct 17, 2025, 08:30 ET Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg Capsules
(tardive dyskinesia). involuntary movements (chorea) of Huntington's disease. INGREZZA or INGREZZA SPRINKLE do not cure the cause of involuntary movements, and do not treat other symptoms of Huntington's disease, such as problems with thinking or emotions.
More news about: Neurocrine Biosciences, Inc.
Oct 17, 2025, 07:01 ET Huntington Bancshares Incorporated Reports 2025 Third-Quarter Earnings
Huntington's senior management will host an earnings conference call on October 17, 2025, at 9:00 a.m. (Eastern Time). The call may be accessed via a live Internet webcast at the Investor Relations section of Huntington's website,
More news about: Huntington Bancshares Incorporated
Oct 15, 2025, 09:03 ET Deck Bio and ReTrax Therapeutics Awarded 2025 Bristol Myers Squibb Golden Tickets
therapy that upregulates FAN1, a DNA-repair enzyme that stabilizes pathogenic repeat expansions, delivering a durable, disease-modifying approach for Huntington's disease (HD) first, with expansion to myotonic dystrophy (DM1) and other repeat expansion disorders (REDs).
More news about: LabCentral
Oct 14, 2025, 12:01 ET Huntington Bank Names David Ortiz Chief Auditor
Ortiz joins Huntington's executive leadership team and will lead the bank's audit organization COLUMBUS, Ohio, Oct.
More news about: Huntington Bancshares Incorporated
Oct 14, 2025, 11:00 ET Huntington Bank Names Sean Richardson President of Huntington Distribution Finance; Announces Jay Turakhia as Regional President for Northeast Ohio
Richardson. "I'm excited to take on this new challenge and continue supporting Huntington's mission to help businesses thrive." In addition to his new role, Richardson will serve as Chairman of Huntington's Cleveland Advisory Board, helping to deepen the bank's engagement with local
More news about: Huntington Bank
Oct 07, 2025, 16:01 ET Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results
and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds
More news about: Neurocrine Biosciences, Inc.
Oct 07, 2025, 11:00 ET Rare Disease Therapeutics Market to Surpass US$ 495.27 Billion by 2033 as Gene Therapy, RNA-based Drugs, and Biologics Transform Patient Care
F. Hoffmann-La Roche Ltd Roche continues to lead in rare disease neurology, with its SMA and Huntington's disease pipelines. In 2025, Roche reported US$ 9 billion in rare disease-related revenues. Novartis
More news about: DataM Intelligence 4 Market Research LLP
Oct 06, 2025, 16:05 ET Huntington Bancshares Incorporated Announces Third Quarter 2025 Earnings Call Details
the Investor Relations section of Huntington's website or through a dial-in telephone number at (877) 407-8029 or (201) 689-8029; conference ID #13756117. A replay of the webcast will be archived in the Investor Relations section of Huntington's website. A telephone replay will
More news about: Huntington Bancshares Incorporated
Oct 06, 2025, 16:05 ET Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise
and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds
More news about: Neurocrine Biosciences, Inc.
Oct 06, 2025, 08:30 ET Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea
Disease Burden in Motor-Related HD-HI Domains Among Adults with Huntington's Disease Treated with Valbenazine (Poster #405) Valbenazine Improves Chorea Across Multiple Body Regions in Adults with Huntington's Disease (Poster #404) Remission of Tardive
More news about: Neurocrine Biosciences, Inc.